Abnormal splicing events can promote drug resistance in a variety of cancer types, however, the full extent of genome-wide splicing in therapy-resistant AML is not fully characterized. This research utilizes a network-based approach to characterize coordinated alternative splicing variation and identify potential splicing event signatures of drug response in AML.